The Time Course of Markers of Neutrophil Extracellular Traps in Patients Undergoing Revascularisation for Acute Myocardial Infarction or Stable Angina Pectoris
Table 1
Clinical characteristics of the study population.
Acute MI group
Stable AP group
Age (yrs)
60 (54–68)
64 (54–71)
ns
Female gender
5
1
ns
Established CAD
0
7
<0.01
Hypertension
7
4
ns
Diabetes mellitus (type 1 or 2)
2
2
ns
Previous or current smoking
10
3
ns
Medication at study inclusion
Acetylsalicylic acid
1
7
<0.01
Clopidogrel
0
0
ns
ACE/AT II antagonists
5
2
ns
Beta-blocker
2
4
0.02
Aldosterone antagonist
0
0
ns
Insulin
0
0
ns
Diuretics
0
0
ns
Statins
1
7
<0.01
Medication at hospital discharge
Acetylsalicylic acid
20
10
ns
Clopidogrel
20
9
ns
ACE/AT II antagonists
11
2
ns
Beta-blocker
18
6
ns
Aldosterone antagonist
0
0
ns
Insulin
0
0
ns
Diuretics
1
0
ns
Statins
20
10
ns
Indices of infarct size and left ventricular function
Peak troponin T (μg/L)
3.8 (2.1–6.1)
Peak CKMB (μg/L)
158 (93–268)
Infarct size (MRI, %)
6.6 (3.2–10.7)
LVEF (MRI, %)
58 (53–66)
Values are given as numbers or medians (25–75 percentiles) unless otherwise stated. CAD: coronary artery disease, defined as previous angina, - or non- infarction, percutaneous intervention (PCI), or coronary artery bypass grafting (CABG). ACE/AT II antagonists: angiotensin converting enzyme/angiotensin II antagonists. CKMB: creatine kinase MB. LVEF: left ventricular ejection fraction. Measured 6 weeks after study inclusion.
